Rituximab for the first-line treatment of stage III-IV follicular lymphoma: (review of NICE technology appraisal guidance 110)

This is an extract from the guidance and may be misleading if read alone. The complete guidance is available at guidance.nice.org.uk/ta243

1 Guidance

This guidance replaces NICE technology appraisal guidance 110 issued in September 2006. For details see 'About this guidance'.

1.1 Rituximab, in combination with:

cyclophosphamide, vincristine and prednisolone (CVP)
cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP)
mitoxantrone, chlorambucil and prednisolone (MCP)
cyclophosphamide, doxorubicin, etoposide, prednisolone and interferon-α (CHVPi) or
chlorambucil

is recommended as an option for the treatment of symptomatic stage III and IV follicular lymphoma in previously untreated people.